Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 11pembrolizumab 8enfortumab vedotin 8Specimen Handling 8Cisplatin 8Magnetic Resonance Spectroscopy 6avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Biopsy 3cabozantinib 2Standard of Care 2Ramucirumab 2Platinum 2Ipilimumab 2Immunoglobulin G 2Doxorubicin 2Docetaxel 2Disulfides 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1relatlimab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × carotuximab × Genitourinary × Clear all
NCT01328574 2017-01-13

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
13 enrolled 15 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡